Drug Trial Radar · NCT06567015
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Sep 17, 2024
Primary completion
Nov 20, 2027
Study completion Jul 2030
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
STX-241Drug
Film-coated tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Part 1 and Part 2: Safety: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.Time frame: Screening to Safety Follow-up (30 days post last dose)
- Part 1 and Part 2: Tolerability: Incidence of TEAEs/SAEs leading to STX-241 dose reductions, interruptions or discontinuations.Time frame: Screening to Safety Follow-up (30 days post last dose)
- Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)Time frame: From first STX-241 intake until 28 days post first dose (28 days post first dose)
- Part 1: Optimal Biologically Active Dose (OBD)Time frame: From the first STX-241 intake up to 24 months
- Part 2: Recommended Phase II Dose (RP2D) of STX-241Time frame: From the first STX-241 intake up to 24 months
- Part 2: cORR (Confirmed Overall Response Rate) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per investigator.Time frame: Up to 24 months
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
Nashville, Tennessee · Recruiting
Oncology Consultants (OC) - Texas Medical Center - Cancer Center
Houston, Texas · Recruiting
Shanghai East Hospital, Tongji University
Shanghai, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
CHU Hôpital de la Timone
Marseille, France · Recruiting
Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau
Saint-Herblain, France · Recruiting
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Germany · Recruiting
Netherlands Cancer Institute
Amsterdam, Netherlands · Recruiting
Hospital Quironsalud Barcelona
Barcelona, Spain · Recruiting
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain · Recruiting
Hospital San Pedro
Logroño, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Centro Intergral Oncologico Clara Campal (CIOCC) (START Madrid)
Madrid, Spain · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.